Novel treatments to prevent and treat hearing loss
In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.
Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.
LEARN MORESound Pharmaceuticals is pleased to announce that it has enrolled the first patient in its Phase 3 clinical trial involving SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3). Additionally, this marks the first Phase 3 trial of an investigational new drug for the treatment of Meniere’s Disease (MD).
Read More
Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that is has received a $1.1M supplement to its $3.1M National Center for Advancing Translational Sciences (NCATS) Award, bringing the total NIH funding to $4.2M. SPI is developing ebselen (SPI-1005), a new molecular entity with anti-viral and anti-inflammatory activity, and enrolling two Phase 2 clinical trials for the treatment of hospitalized COVID-19 patients.
Read More
Sound Pharmaceuticals, Inc. (SPI) is pleased to announce a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1M to support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of patients with COVID-19.
Read More
Oral treatments for acute and chronic hearing loss
Oral combination for the treatment of acute ototoxicity
LEARN MORELocally delivered treatments for hearing restoration
LEARN MORE
